Denali Therapeutics
DNLI
78 hedge funds and large institutions have $1.46B invested in Denali Therapeutics in 2018 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 38 increasing their positions, 11 reducing their positions, and 8 closing their positions.
245% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 11
138% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 8
53% more capital invested
Capital invested by funds: $949M → $1.46B (+$507M)
16% more funds holding
Funds holding: 67 → 78 (+11)
4.77% more ownership
Funds ownership: 65.87% → 70.64% (+4.8%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$36.2M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$27.5M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$12.6M |
| 4 |
State Street
Boston,
Massachusetts
|
+$9.89M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$8.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
-$28.9M |
| 2 |
AI
Alphabet Inc
Mountain View,
California
|
-$8.18M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.39M |
| 4 |
Millennium Management
New York
|
-$2.62M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$753K |
DNLI Hedge Fund Activity: Q3 2018 in Review
78 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q3 2018, worth a combined $1.46B — up 53% from $949M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new DNLI positions and 8 closed out — a net gain of 11 holders — while 38 added to existing stakes and 11 trimmed.
The largest buyer was BlackRock, adding an estimated $36.2M. The largest seller was Fidelity International, cutting an estimated $28.9M.
- 78 institutional investors held Denali Therapeutics (DNLI) as of Q3 2018, up from 67 in Q2 2018.
- Funds reported $1.46B of Denali Therapeutics stock for Q3 2018, up 53% quarter-over-quarter.
- 19 funds opened new Denali Therapeutics positions in Q3 2018 and 8 closed out, a net change of +11 holders.
- The largest Denali Therapeutics buyer in Q3 2018 was BlackRock, an estimated $36.2M added.
- The largest Denali Therapeutics seller in Q3 2018 was Fidelity International, an estimated $28.9M sold.
Based on aggregated 13F filings for Q3 2018.